Groupama Asset Managment Acquires 21,037 Shares of Hologic, Inc. (NASDAQ:HOLX)

Groupama Asset Managment grew its holdings in Hologic, Inc. (NASDAQ:HOLX) by 63.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 54,214 shares of the medical equipment provider’s stock after purchasing an additional 21,037 shares during the period. Groupama Asset Managment’s holdings in Hologic were worth $3,918,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of HOLX. General Partner Inc. purchased a new position in Hologic in the 4th quarter valued at approximately $26,000. Venturi Wealth Management LLC grew its position in shares of Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after purchasing an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 260 shares in the last quarter. Smartleaf Asset Management LLC raised its stake in shares of Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 159 shares during the period. Finally, Smithfield Trust Co lifted its holdings in Hologic by 160.0% during the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 400 shares in the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. William Blair reiterated an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Evercore ISI reduced their price objective on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a research note on Thursday, February 6th. Jefferies Financial Group initiated coverage on shares of Hologic in a research note on Tuesday, December 10th. They issued a “hold” rating and a $85.00 target price on the stock. Needham & Company LLC lowered shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price target for the company. in a research report on Monday, February 3rd. Finally, Wolfe Research started coverage on shares of Hologic in a report on Friday, December 13th. They issued a “peer perform” rating on the stock. Eleven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $84.62.

Hologic Trading Down 0.6 %

Shares of HOLX opened at $61.38 on Wednesday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic, Inc. has a fifty-two week low of $60.34 and a fifty-two week high of $84.67. The firm has a 50 day moving average price of $64.90 and a 200-day moving average price of $72.97. The firm has a market cap of $13.77 billion, a price-to-earnings ratio of 19.36, a PEG ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, equities research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.